Respiratory Inhalers Market

Respiratory Inhalers Market By Product Type (Dry Powder Inhalers, Metered Dosed Inhalers, Soft Mist Inhalers, Nebulizers[Mesh Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers]), By Type (Conventional Inhaler Devices And Smart Inhaler Devices), By Patient Type (Adult And Pediatric), By Indication (Asthma, COPD, Others) and by geography is estimated to register growth at a remarkable CAGR during the forecast period 2023-2028 owing to the increasing prevalence of respiratory disorders such as asthma, COPD, and others, the rising air pollution and the growing number of product development activities such as product launches and regulatory approvals

The global respiratory inhalers market was valued at USD 30,267.49 million in 2021 and is estimated to grow at a CAGR of 4.65% during the forecast period of (2023–2028) to reach USD 40,540.87 million by 2028. The Respiratory Inhalers market is slated to witness prosperity owing to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others, the surge in the adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for Respiratory Inhalers during the forecast period (2023-2028).

Respiratory Inhalers Market Dynamics:

One of the noteworthy drivers of the respiratory inhalers market is the rising prevalence of respiratory disorders such as asthma, COPD, cystic fibrosis, among others.

For example, as per data by the World Health Organization (2023), asthma affected approximately 262 million people in 2019, causing 455,000 deaths in the same year, globally. Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.

Moreover, the rising air pollution is also expected to drive the demand for respiratory inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.

Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the respiratory inhalers market. For example, in September 2019, Boehringer Ingelheim launched the first reusable soft mist inhaler Respimat® re-usable that can be used with up to six cartridges, reducing the carbon footprint further by 71%.

Thus, the interplay of all the above-mentioned factors is expected to add a positive impact on the respiratory inhalers market, which will further boost the demand for respiratory inhalers during the forecast period.

However, the availability of alternate route of administration, high of inhalers and the safety concerns coupled with these devices, may act as restraining factors for the respiratory inhalers market growth.

The COVID- 19 pandemic had a slightly negative impact on the market growth of respiratory inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the respiratory inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in respiratory inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers for the testing of lung function, driving the market growth for respiratory inhalers.

Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for respiratory inhalers is subjected to increase driving the overall market for respiratory inhalers.

Respiratory Inhalers Market Segment Analysis:

Respiratory Inhalers market by product type (dry powder inhalers, metered dosed inhalers, soft mist inhalers, nebulizers [mesh nebulizers, jet nebulizers, ultrasonic nebulizers]), type (conventional inhaler devices and smart inhaler devices), patient type (adult and pediatric), indication (asthma, COPD, others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

Based on the type segment, the smart inhaler devices is expected to hold the maximum revenue share in the respiratory inhalers market and was valued at USD 46.50 million in 2021 and will grow at a CAGR of 15.63% during the forecast period (2023–2028) to reach USD 113.20 million by 2028.

This can be attributed to the technological superiority, compatibility, and the increasing product development activities such as product regulatory approvals in the smart inhaler devices segment during the forecast period.

Smart inhalers serve enormous benefits for adults and the geriatric population who may find difficulties in taking up the same amount of puffs due to unequal breath. According to the U.S Department of Health and Human Services (2023), with old age, the muscles supporting breathing and the diaphragm, becomes weakened, preventing from breathing enough air in or out. Smart inhalers can be employed in these cases. Smart inhalers, equipped with sensors attach to conventional inhalers and helps to keep a track of timing of medication. Also, being Bluetooth-enabled, they can be remotely coupled with a computer or a smart device like a phone or tablet to transport data from the smart inhaler automatically.

Along with numerous advantages of the device, the growing product approvals is also expected to bolster the demand for smart inhalers in the forthcoming years. For instance, in January, 2020, FDA approved the CapMedic smart inhaler cap from Cognita Labs, which is capable of transmitting signals to patients to use inhalers correctly.

Hence, the interplay of all the aforementioned factors is anticipated to propel the market for aspheric monofocal Respiratory Inhalers during the forecast period.

North America is expected to dominate the overall Respiratory Inhalers Market:

Among all the regions, North America is expected to lead in revenue generation in the global respiratory inhalers market and was valued at USD 13,514.14 million in 2021. It will grow at a CAGR of 4.08% during the forecast period from 2023 to 2028 to reach USD 17,525.98 million by 2028.

This domination is due to the increasing prevalence of various respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, among others, increasing exposure of smoking, dust, and chemicals, and various initiatives by government bodies for respiratory healthcare, and others in the North America region. Furthermore, research and development activities in the region associated with the launch of new respiratory inhalers are also driving the market growth in North America.

As per the data published by World Health Organization (WHO) 2021, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people. According to the National Center for Health Statistics 2020–2021, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.

In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2021, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 – 2021.

In addition to the above factors, the growing product development activities is also expected to drive the demand for respiratory inhalers in the North America region. For instance, in September 2020, Teva Respiratory, LLC., a United States affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, two digital maintenance inhalers for patients with asthma. In a similar instance, in October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.

Therefore, the increasing product developmental activities, the rising prevalence of respiratory disorders and the large patient population associated with them, is expected to drive the demand for respiratory inhalers, thereby driving the overall respiratory inhalers during the forecast period.

Respiratory Inhalers Market Key Players:

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A, Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, . Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Rossmax International Ltd, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc, Microlife Corporation, HONSUN, and others.

Recent Developmental Activities in Respiratory Inhalers Market:

• In October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.
• In September 2020, Teva Respiratory, LLC., a United States affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, two digital maintenance inhalers for patients with asthma.
• In September 2019, Boehringer Ingelheim launched the first reusable soft mist inhaler Respimat® re-usable that can be used with up to six cartridges, reducing the carbon footprint further by 71%.

Key Takeaways from the Respiratory Inhalers Market Report Study

• Market size analysis for current market size (2023), and market forecast for 5 years (2023-2028)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Respiratory Inhalers market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the Global Respiratory Inhalers Market.
• Various opportunities available for the other competitor in the Respiratory Inhalers Market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028.
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Respiratory Inhalers market growth in the coming future?

Target Audience who can be benefited from the Respiratory Inhalers Market Report Study

• Respiratory Inhalers providers
• Research organizations and consulting companies
• Respiratory Inhalers-related organization, association, forum, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders in Respiratory Inhalers
• Various End-users who want to know more about the Respiratory Inhalers Market and the latest technological developments in the Respiratory Inhalers market.

Frequently Asked Questions for the Respiratory Inhalers Market:

1. What are the Respiratory Inhalers?

Respiratory inhalers are portable medical devices used to treat disorders of the respiratory tract such as asthma and chronic obstructive pulmonary disease (COPD). Exacerbations of these persistent disorders are prevented and treated using respiratory inhalers.

2. What is the market for the global Respiratory Inhalers?

The global Respiratory Inhalers market was valued at USD 30,267.49 million in 2021 and is estimated to grow at a CAGR of 4.65% during the forecast period (2023–2028) to reach USD 40,540.87 million by 2028.

3. What are the drivers for the global Respiratory Inhalers market?

The Respiratory Inhalers market is slated to witness prosperity owing to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others, the surge in the adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for Respiratory Inhalers during the forecast period (2023-2028).

4. Who are the key players operating in the global Respiratory Inhalers market?

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A, Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, . Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Rossmax International Ltd, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc, Microlife Corporation, HONSUN, and others.

5. Which region has the highest share in the Respiratory Inhalers market?

North America is expected to dominate the overall Respiratory Inhalers market during the forecast period, 2023 to 2028. This can be ascribed to the increasing prevalence of various respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, among others, increasing exposure of smoking, dust, and chemicals, and various initiatives by government bodies for respiratory healthcare, and others in the North America region. Furthermore, research and development activities in the region associated with the launch of new respiratory inhalers are also driving the market growth in North America.